title: [Subclinical pro-thrombotic state in a relapse of Behcet's disease--case report].
abstract: A patient, aged 34, with a relapse of Behcet's disease (BD) showed laboratory features of enhanced coagulation activation without any symptoms of arterial or venous thrombosis. Elevated levels of thrombin-antithrombin III complexes (TAT), prothrombin fragments 1 + 2 (F1 + 2), associated with impairement of fibrinolysis were found. Total fibrinolytic activity, measured on fibrin plates, plasma concentration of tissue-type plasminogen activator (tPA:Ag) and plasmin-alpha 2-antiplasmin complexes (PAP) were low, whereas plasminogen activator inhibitor 1 concentration (PAI-1:Ag) was elevated in comparison with normal values. There intravenous 500 mg doses of cyclophosphamide, given on day 0, 7 and 50, resulted in a marked clinical improvement. This was accompanied by the normalization of augmented thrombin generation and increased fibrinolytic activity. This is the first report to show prothrombotic tendency in a relapse of Behcet disease and beneficial effect of cyclophosphamide therapy on haemostatic abnormalities. A degree of activation of coagulative and fibrinolytic system seems to be of importance in the pathogenesis of Behcet's disease, and monitoring of hemostatic parameters could be helpful in clinical assessment.
authors.affiliation: II Katedry Chorób Wewnetrznych Collegium Medicum Uniwersytetu Jagiellońskiego, Krakowie.
authors.forename: A
authors.initials: A
authors.lastname: Undas
authors.forename: G
authors.initials: G
authors.lastname: Pinis
mesh_terms: D000328:Adult; D001528:Behcet Syndrome / Q000150:complications* / Q000503:physiopathology; D001778:Blood Coagulation Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D003520:Cyclophosphamide / Q000627:therapeutic use; D006487:Hemostasis / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008297:Male; D012008:Recurrence
chemical_list: D003520:Cyclophosphamide